Affiliation:
1. Department of Hematology, Yinzhou People's Hospital, Ningbo, Zhejiang, 315040, P.R. China
Abstract
Background:
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
whose known drug treatments are limited and expensive.
Objective:
This investigation aimed to investigate the therapeutic potential of anlotinib in B-cell acute lymphoblastic
leukemia (B-ALL).
Methods:
The B-ALL cell lines Nalm-6 and BALL-1 were used to verify the therapeutic potential of anlotinib in BALL.
The cell activity was measured by Cell Counting Kit-8. Apoptosis was detected by Annexin V-FITC/PI double
staining combined with flow cytometry. Afterward, the binding capacity of anlotinib to the critical protein was predicted
by molecular docking, and the protein changes in the related pathways downstream of the target proteins were verified
by western blot. Finally, the effect of anlotinib on the survival rate was verified in B-ALL nude mice.
Results:
Anlotinib inhibited the proliferation of the B-ALL cell lines, Nalm-6, and BALL-1, and promoted apoptosis.
Molecular docking results showed that it had the potential binding ability to BTK. Western blot revealed that anlotinib
was able to inhibit the phosphorylation of BTK, AKT, and mTOR, thereby inhibiting the proliferation of B-ALL cells.
In addition, anlotinib suppressed weight loss and prolonged the survival time of mice.
Conclusion:
To summarize, anlotinib can inhibit the proliferation of B-ALL and promotes apoptosis by inhibiting the
phosphorylation of BTK and AKT, and mTOR.
Funder
Ningbo Yinzhou District Agricultural and Social Development Science and Technology Project
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference32 articles.
1. Imai K.; Acute lymphoblastic leukemia: Pathophysiology and current therapy. Rinsho Ketsueki 2017,58(5),460-470
2. Kantarjian H.M.; Thomas D.; Ravandi F.; Faderl S.; Jabbour E.; Garcia-Manero G.; Pierce S.; Shan J.; Cortes J.; O’Brien S.; Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010,116(24),5568-5574
3. Gutierrez-Camino Á.; Umerez M.; Martin-Guerrero I.; García de Andoin N.; Santos B.; Sastre A.; Echebarria-Barona A.; Astigarraga I.; Navajas A.; Garcia-Orad A.; Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J 2018,18(6),704-712
4. Goodman P.A.; Wood C.M.; Vassilev A.O.; Mao C.; Uckun F.M.; Defective expression of Bruton’s tyrosine kinase in acute lymphoblastic leukemia. Leuk Lymphoma 2003,44(6),1011-1018
5. Katz F.E.; Lovering R.C.; Bradley L.A.; Rigley K.P.; Brown D.; Cotter F.; Chessells J.M.; Levinsky R.J.; Kinnon C.; Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia 1994,8(4),574-577